Wet Heparinized Suction for Abdominal Cancer
Reason given: study no longer proceeding
Key facts
- Where
- Tampa, United StatesSee the site
Where in United States
- Moffitt Cancer CenterTampa, United StatesNo longer taking part
Trial details
- Who runs it
- H. Lee Moffitt Cancer Center and Research Institute
- Trial code
- NCT05041335
- Record updated
- 17 September 2026
- Original description
The purpose of this research is to compare the amount and quality of tissue obtained by EUS-FNB when the device is flushed with an anticoagulant or "blood thinner" vs. saline a salt water solution as well as the use of a microsieve in order for the doctor to look at the tissue to check the acceptability of the specimens before sending for analysis.Read full original descriptionShow less
Wet Heparinized Suction: A Novel Technique to Enhance Tissue Acquisition for Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB) of Solid Abdominal Masses: A Randomized Prospective Trial
The purpose of this research is to compare the amount and quality of tissue obtained by EUS-FNB when the device is flushed with an anticoagulant or "blood thinner" vs. saline a salt water solution as well as the use of a microsieve in order for the doctor to look at the tissue to check the acceptability of the specimens before sending for analysis.
You will be randomly assigned (like a flip of a coin) to have either the blood thinner or the salt water solution placed within the needle being used to sample your abdominal tumor and to have either a sieve used or not.
You will be one of 42 participants enrolled in this data collection study which includes 1 sites in the United States.
Inclusion: Age ≥ 18 year; Non-pregnant Patients; Patients with the presence of a solid abdominal mass as seen on diagnostic imaging [ie. ultrasound (US), computer tomography (CT) or magnetic resonance imaging (MRI)] scheduled to undergo EUS examination OR Patients who underwent a prior EUS-FNA/FNB for solid pancreatic mass and did not receive a conclusive diagnosis; Patients with platelet count > 50,000; Patients with International Normalized Ratio (INR) < 1.5.
Exclusion: Patients with prior heparin induced thrombocytopenia (HIT); Patients with a heparin or porcine allergy; Patients with anticoagulants or anti-platelet agents (excluding aspirin) within the last 7-10 days; Patients with a platelet count < 50,000; Patients with an INR > 1.5; Age < 18 years; Pregnant Patients; Patients who cannot consent for themselves; Patients with cystic abdominal masses; Patient's with religious aversion to porcine-containing products.